Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
ORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome.
JCI Insight. 2024 Mar 5;9(6):e174866. doi: 10.1172/jci.insight.174866.
JCI Insight. 2024.
PMID: 38516893
Free PMC article.
Pathogenic DPAGT1 variants in limb-girdle congenital myasthenic syndrome (LG-CMS) associated with tubular aggregates and ORAI1 hypoglycosylation.
Brande LV, Bauché S, Pérez-Guàrdia L, Sternberg D, Seferian AM, Malfatti E, Silva-Rojas R, Labasse C, Chevessier F, Carlier P, Eymard B, Romero NB, Laporte J, Servais L, Gidaro T, Böhm J.
Brande LV, et al. Among authors: perez guardia l.
Neuropathol Appl Neurobiol. 2023 Dec 20:e12952. doi: 10.1111/nan.12952. Online ahead of print.
Neuropathol Appl Neurobiol. 2023.
PMID: 38124360
Item in Clipboard
Silencing of the Ca2+ Channel ORAI1 Improves the Multi-Systemic Phenotype of Tubular Aggregate Myopathy (TAM) and Stormorken Syndrome (STRMK) in Mice.
Silva-Rojas R, Pérez-Guàrdia L, Lafabrie E, Moulaert D, Laporte J, Böhm J.
Silva-Rojas R, et al. Among authors: perez guardia l.
Int J Mol Sci. 2022 Jun 23;23(13):6968. doi: 10.3390/ijms23136968.
Int J Mol Sci. 2022.
PMID: 35805973
Free PMC article.
Item in Clipboard
Cite
Cite